Axumin® PET/CT Scan
Subjects in the clinical study will undergo PET/CT scans. This scan combines two imaging techniques. A positron emission tomography (PET) scan shows physiologic (functional) changes in the body, and a computed tomography (CT) scan shows a detailed depiction of your anatomy, where tumors may reside. The two imaging techniques provide the physician with detailed information about the extent and location of your disease.
The PET component of the PET/CT uses Axumin®. It is an FDA-approved diagnostic imaging agent, also known as a "tracer," that may help your physician better determine the location of any prostate cancer that is present. Further information on Axumin® can be provided at your request from our Medical Liaison.